Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery, Abcam Ink Licensing Deal

NEW YORK (GenomeWeb) – Horizon Discovery Group and Abcam today announced a licensing and supply agreement that gives Abcam exclusive access to more than 1,800 human diploid and haploid cell lines from Horizon's X-MAN collection. 

The cell lines will help in the validation of Abcam's existing monoclonal and polyclonal antibodies marketed to researchers, the firms said, and Horizon will develop additional haploid cell lines to validate new antibodies from Abcam. 

They said that data from Abcam will add value to Horizon's cell line collection by independently demonstrating that the cell lines provide "the desired functional output of gene editing," as well as time and costs savings. The new cell lines generated by Abcam will become available to Horizon's customers across all of its core products and services, the partners said. 

Under the terms of the deal, Abcam will pay Horizon an initial £660,000 ($1 million) during an exclusive period of three years. If Abcam extends the exclusivity period, Horizon will receive an additional £1,275,000 in years four through six. 

For any additional haploid cell lines developed, preferred pricing will be charged, and Horizon will receive a royalty on the sale of Abcam antibodies that are marketed using validation data derived from Horizon cells lines for 10 years from the first date of sale. 

The firms said that beyond the initial term of the deal, they may extend the collaboration to cover the entire human proteome. They also said that they may co-develop novel functional genomic products and services.